Equities analysts expect Syneos Health Inc (NASDAQ:SYNH) to announce sales of $983.88 million for the current fiscal quarter, Zacks Investment Research reports. Six analysts have made estimates for Syneos Health’s earnings. The lowest sales estimate is $876.30 million and the highest is $1.05 billion. Syneos Health posted sales of $1.17 billion in the same quarter last year, which would indicate a negative year over year growth rate of 15.9%. The company is expected to issue its next quarterly earnings report on Tuesday, August 4th.
On average, analysts expect that Syneos Health will report full-year sales of $4.40 billion for the current financial year, with estimates ranging from $4.22 billion to $4.66 billion. For the next year, analysts expect that the company will post sales of $4.94 billion, with estimates ranging from $4.67 billion to $5.29 billion. Zacks’ sales averages are an average based on a survey of research firms that cover Syneos Health.
Syneos Health (NASDAQ:SYNH) last issued its earnings results on Thursday, April 30th. The company reported $0.68 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.64 by $0.04. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.14 billion. Syneos Health had a net margin of 4.13% and a return on equity of 10.33%. The business’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.59 earnings per share.
In other news, insider Michelle Keefe sold 2,500 shares of Syneos Health stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $60.00, for a total transaction of $150,000.00. Following the completion of the sale, the insider now directly owns 51,943 shares in the company, valued at $3,116,580. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Jason M. Meggs purchased 3,555 shares of the stock in a transaction dated Friday, March 20th. The shares were purchased at an average price of $36.74 per share, with a total value of $130,610.70. Following the completion of the acquisition, the chief financial officer now owns 63,784 shares of the company’s stock, valued at $2,343,424.16. The disclosure for this purchase can be found here. Insiders own 0.44% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in SYNH. Louisiana State Employees Retirement System grew its holdings in Syneos Health by 1.3% in the fourth quarter. Louisiana State Employees Retirement System now owns 15,100 shares of the company’s stock valued at $898,000 after purchasing an additional 200 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Syneos Health by 8.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,921 shares of the company’s stock valued at $233,000 after purchasing an additional 309 shares during the period. Rothschild Investment Corp IL purchased a new stake in Syneos Health in the fourth quarter valued at approximately $383,000. State of Michigan Retirement System grew its holdings in Syneos Health by 1.7% in the fourth quarter. State of Michigan Retirement System now owns 18,300 shares of the company’s stock valued at $1,088,000 after purchasing an additional 300 shares during the period. Finally, New York State Teachers Retirement System grew its holdings in Syneos Health by 38.8% in the fourth quarter. New York State Teachers Retirement System now owns 27,200 shares of the company’s stock valued at $1,618,000 after purchasing an additional 7,600 shares during the period.
Shares of NASDAQ:SYNH traded up $0.18 during midday trading on Monday, hitting $59.73. The stock had a trading volume of 253,102 shares, compared to its average volume of 545,726. The company has a market capitalization of $6.20 billion, a PE ratio of 32.29 and a beta of 1.79. The stock has a 50 day moving average price of $50.56 and a two-hundred day moving average price of $55.38. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 1.03. Syneos Health has a 1 year low of $30.02 and a 1 year high of $74.25.
Syneos Health Company Profile
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.